Browse the corpus

REFERENCES Arpino PA, Demirjian Z, and Van Cott EM, “Use of the Chromogenic Factor X Assay to Predict the International Normalized Ratio in Patients Transitioning from Argatroban to Warfarin,” Pharmacotherapy , 2005, 25(2):157-64. [PubMed 15767231 ] Baghdasarian SB, Singh I, Militello MA, et al, “Argatroban Dosage in Critically Ill Patients With HIT,” Blood 2004, 104:1779 [abstract 1779 from 2004 ASH Annual Meeting]. Beiderlinden M, Treschan TA, Gorlinger K, et al, “Argatroban Anticoagulation in Critically Ill Patients,” Ann Pharmacother , 2007, 41(5):749-54. [PubMed 17440009 ] Dager WE and White RH, “Pharmacotherapy of Heparin-Induced Thrombocytopenia,” Expert Opin Pharmacother , 2003, 4(6):919-40. [PubMed 12783589 ] de Denus S and Spinler SA, “Decreased Argatroban Clearance Unaffected by Hemodialysis in Anasarca,” Ann Pharmacother , 2003, 37(9):1237-40. [PubMed 12921506 ] Garcia DA, Baglin TP, Weitz JI, et al, “Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest , 2012, 141(2 Suppl):24-43. [PubMed 22315264 ] Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest , 2012, 141(2 Suppl):7-47. [PubMed 22315257 ] Honisko ME, Fink JM, Militello MA, et al, “Compatibility of Argatroban With Selected Cardiovascular Agents,” Am J Health Syst Pharm , 2004, 61(22):2415-8. [PubMed 15581266 ] Hursting NJ and Jang IK, "Impact of Renal Function on Argatroban Therapy During Percutaneous Coronary Intervention," J Thromb Thrombolysis , 2010 29(1):1-7. [PubMed 19504050 ] Levine RL, Hursting MJ, and McCollum D, "Argatroban Therapy in Heparin-Induced Thrombocytopenia With Hepatic Dysfunction," Chest , 2006, 129(5):1167-75. [PubMed 16685006 ] Lewis BE, Matthai WH, Cohen M, et al, “Argatroban Anticoagulation During Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia,” Catheter Cardiovasc Interv , 2002, 57(2):177-84. [PubMed 12357516 ] Lewis BE, Wallis DE, Berkowitz SD, et al, “Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia,” Circulation , 2001, 103(14):1838-43. [PubMed 11294800 ]

Lewis BE, Matthai WH, Cohen M, et al, “Argatroban Anticoagulation During Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia,” Catheter Cardiovasc Interv , 2002, 57(2):177-84. [PubMed 12357516 ] Lewis BE, Wallis DE, Berkowitz SD, et al, “Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia,” Circulation , 2001, 103(14):1838-43. [PubMed 11294800 ] Link A, Girndt M, Selejan S, et al, “Argatroban for Anticoagulation in Continuous Renal Replacement Therapy,” Crit Care Med , 2009, 37(1):105-10. [PubMed 19050602 ] Linkins L, Dans AL, Moores LK, et al, “Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest , 2012, 141(2 Suppl):e495-530. [PubMed 22315270 ] Murray PT, Reddy BV, Grossman EJ, et al, “A Prospective Comparison of Three Argatroban Treatment Regimens During Hemodialysis in End-Stage Renal Disease,” Kidney Int , 2004, 66(6):2446-53. [PubMed 15569338 ] Reichert MG, MacGregor DA, Kincaid EH, et al, “ Excessive Argatroban Anticoagulation for Heparin-Induced Thrombocytopenia,” Ann Pharmacother , 2003, 37(5):652-4. [PubMed 12708939 ] Rice L, Hursting MJ, Baillie GM, et al, “Argatroban Anticoagulation in Obese Versus Nonobese Patients: Implications for Treating Heparin-Induced Thrombocytopenia,” J Clin Pharmacol , 2007, 47(8):1028-34. [PubMed 17525167 ] Tang IY, Cox DS, Patel K, et al, “Argatroban and Renal Replacement Therapy in Patients With Heparin-Induced Thrombocytopenia,” Ann Pharmacother , 2005, 39(2):231-6. [PubMed 15632219 ] Yarbrough PM, Varedi A, Walker A, et al, “Argatroban Dose Reductions for Suspected Heparin-Induced Thrombocytopenia Complicated by Child-Pugh Class C Liver Disease,” Ann Pharmacother , 2012,46(11):e30. [PubMed 23073302 ] Topic 8765 Version 41.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0603-122.72.76.133-B1A854215F-S244013.14]